USFDA concludes inspection at Natco Pharma’s API manufacturing plant in Manali

21 Nov 2025 Evaluate

The U.S. Food and Drug Administration (USFDA) has concluded inspection at Natco Pharma’s Active Pharmaceutical Ingredients (API) manufacturing plant located in Manali, Chennai.  The said inspection was conducted from November 17, 2025 to November 21, 2025. 

On conclusion of the inspection, the company received seven observations in the Form-483. The company remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.


Natco Pharma Share Price

824.05 -21.15 (-2.50%)
20-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1377.85
Zydus Lifesciences 872.95
Lupin 2166.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×